Patents by Inventor Adriana Donovan

Adriana Donovan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
    Publication number: 20230190929
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 22, 2023
    Inventors: Gregory J. CARVEN, Michelle STRAUB, Adriana DONOVAN, Katherine Jane TURNER
  • Methods for using anti-myostatin antibodies
    Patent number: 11439704
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: September 13, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Gregory J. Carven, Michelle Straub, Adriana Donovan, Katherine Jane Turner
  • METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION
    Publication number: 20220106390
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Application
    Filed: September 22, 2021
    Publication date: April 7, 2022
    Inventors: Adriana DONOVAN, Michelle STRAUB, Stefan WAWERSIK, Yung CHYUNG, Micah WEBSTER
  • RGMC-SELECTIVE INHIBITORS AND USE THEREOF
    Publication number: 20210380669
    Abstract: Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 9, 2021
    Inventors: Samantha Nicholls, Adriana Donovan, Meghan McDonald, Abhishek Datta, Allan Capili, Kevin B. Dagbay, Lorena Lerner, Leonard Ira Zon, Kevin Schutz, John Bukowski, Justin W. Jackson
  • METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES
    Publication number: 20210332117
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Application
    Filed: October 29, 2020
    Publication date: October 28, 2021
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Compositions and methods for making and using anti-myostatin antibodies
    Patent number: 11155611
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 26, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Stefan Wawersik, Yung Chyung, Micah Webster
  • USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
    Publication number: 20210283166
    Abstract: The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.
    Type: Application
    Filed: February 3, 2021
    Publication date: September 16, 2021
    Inventors: Kimberly LONG, Adriana DONOVAN, Yung CHYUNG, Michelle STRAUB
  • Use of myostatin inhibitors and combination therapies
    Patent number: 10946036
    Abstract: The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: March 16, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Kimberly Long, Adriana Donovan, Yung Chyung, Michelle Straub
  • ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
    Publication number: 20210046180
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Application
    Filed: June 24, 2020
    Publication date: February 18, 2021
    Applicant: Scholar Rock, Inc.
    Inventors: Gregory J. CARVEN, Michelle STRAUB, Adriana DONOVAN, Katherine Jane TURNER
  • Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
    Patent number: 10882904
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 5, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Anti-pro/latent-Myostatin antibodies and uses thereof
    Patent number: 10751413
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: August 25, 2020
    Assignee: Scholar Rock, Inc.
    Inventors: Gregory J. Carven, Michelle Straub, Adriana Donovan, Katherine Jane Turner
  • METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION
    Publication number: 20190345239
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 14, 2019
    Inventors: Adriana DONOVAN, Michelle STRAUB, Stefan WAWERSIK, Yung CHYUNG, Micah WEBSTER
  • USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES
    Publication number: 20190255093
    Abstract: The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.
    Type: Application
    Filed: June 13, 2017
    Publication date: August 22, 2019
    Inventors: Kimberly Long, Adriana Donovan, Yung Chyung, Michelle Straub
  • METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES
    Publication number: 20190218283
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Application
    Filed: March 21, 2019
    Publication date: July 18, 2019
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
    Patent number: 10287345
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
    Publication number: 20180344844
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Application
    Filed: September 15, 2016
    Publication date: December 6, 2018
    Inventors: Gregory J. Carven, Michelle Straub, Adriana Donovan, Katherine Jane Turner
  • ANTI-PRO/LATENT MYOSTATIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170198032
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Applicant: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Ferroportin1 nucleic acids, proteins, antibodies and methods
    Patent number: 8133974
    Abstract: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: March 13, 2012
    Assignee: Children's Medical Center Corporation
    Inventors: Leonard I. Zon, Adriana Donovan
  • Ferroportin1 nucleic acids, proteins, antibodies and methods
    Publication number: 20100048862
    Abstract: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof.
    Type: Application
    Filed: March 16, 2009
    Publication date: February 25, 2010
    Applicant: Children's Medical Center Corporation
    Inventors: Leonard I. Zon, Adriana Donovan
  • Ferroportin1 antibodies and methods
    Patent number: 7521055
    Abstract: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: April 21, 2009
    Assignee: Children's Medical Center Corporation
    Inventors: Leonard I. Zon, Adriana Donovan